anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) are severe demyelinating inflammatory autoimmune neurological disorders. The estimated global pooled prevalence of NMOSD is 1.82 per 100 000 people (Etemadifar et al. 2015). The disorder is characterized by inflammatory lesions in the optic nerve, spinal cord, brainstem, and cerebrum; and clinically by optic neuritis (ON) and/or transverse myelitis causing potentially severe motor and sensory impairment, bladder dysfunction, vision loss, pain, and other debilitating symptoms (Wingerchuk et al. 2015). Recovery is variable, and inflammatory attacks often result in permanent disability. Untreated, the risks of severe disability or death are substantial (Jarius et al. 2014).

NMOSD is radiologically and prognostically distinct from multiple sclerosis (MS), and has a pathophysiology unresponsive to typical MS treatment (Weinshenker 2007; Oh, and Levy et al. 2012).
PURPOSE:To industrially and advantageously obtain a polysaccharide MA9 which is an antitumor agent, by extracting a tree bark of Melia azadirachta Linn. with hot water, purifying the resultant extract at a specific pH by an alcohol precipitation method and further purifying the precipitates by a gel filtration method. CONSTITUTION:A tree bark of Melia azadirachta Linn. is extracted with hot water and the resultant extract solution is adjusted to 1-3pH. An alcohol is then added to collect the formed precipitates, which are then dissolved in water. The above-mentioned aqueous solution is subjected to gel filtration and the initial fraction of trisected polysaccharide fractions is collected. The solvent is then removed to afford the aimed polysaccharide MA9. Methanol or ethanol is preferred for the alcohol to be added. The alcohol is preferably added in an amount to give 20-90%, particularly about 80% alcohol concentration. The purity of the product can be remarkably improved by simple operation to adjust the pH of the extract solution in the alcohol precipitation method.
Single centre, Phase I, double-blind, randomised, placebo-controlled study investigating 4 multiple rising oral doses of BIA 2-093 in 4 groups of 8 young healthy male subjects. Within each group, 2 subjects were randomised to receive placebo and the remaining 6 subjects to receive BIA 2-093. No subject was a member of more than one group. The dose regimens investigated were: 200 mg b.i.d.(twice daily), 400 mg o.d.(once daily; this was changed from 400 mg b.i.d. in protocol amendment 1, on the basis of interim pharmacokinetic analysis of Group 1 data), 800 mg o.d, and 1200 mg o.d. BIA 2-093/placebo was administered orally once daily on Days 1-8, or twice a day (at 12-hour intervals) on Days 1-7 with a final dose in the morning of Day 8. The multiple dose regimens were to be investigated in ascending order. Progression to each higher dose level was only to occur if the previous dose level was deemed by the investigator and the sponsor to be safe and well tolerated.
Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
The invention discloses a rare-earth organic framework material for fluorescent temperature sensation imaging in biological tissue and cells. The rare-earth organic framework material has the long-range ordered crystal structure and regular pores. The chemical formula is [LnLx(G)(H2O)].(G)n, wherein Ln is rare earth Eu or Tb, L is an organic ligand simultaneously containing benzene carboxylic acid group and triazinyl group, G represents a solvent molecule which is coordinated with rare-earth ions or in the crystal pores, x=1-3, and n=1-4. The rare-earth organic framework material is prepared by the solvothermal method which is simple and has higher yield. The micro/nano rare-earth organic framework material has the characterized light emissions of two types of rare-earth ions; the strength ratio of the two peaks has favorable exponential relation to the temperature; the temperature detection range is 20-80 DEG C; as the temperature increases, the luminous color can turn red from green; and the rare-earth organic framework material has favorable biocompatibility and heat stability, can implement real-time temperature imaging in biological tissues, and is hopeful to be applied in the aspects of biomedical treatment and the like.
PURPOSE:To obtain the titled preparation containing lactitol as an active ingredient. CONSTITUTION:Lactitol (4-beta-D-galactopyranosyl-D-sorbitol) as an active ingredient is blended with a carrier (e.g. lactose, starch, dextrin, white sugar, crystalline cellulose, kaolin, calcium carbonate, talc, calcium stearate, etc.) to give a conservative treatment agent for renal insufficiency. The agent is a drug which reduces methylguanidine in blood, promotes excretion of urea and creatinine, has inhibitory action on production of ammonia, etc., and on intestine absorption and shows progression retarding effects on renal insufficiency, progress suppressing effect on renal insufficiency, retarding effects on blood hemodialysis introduction period in renal insufficiency, improving and suppressing effects on renal function reduction in renal insufficiency, suppressing effects on occurrence of uremia. A dose is 20-40g/day/person in the case of oral administration. Tablet, film tablet, capsule, powder, granule, injection, etc., may be cited as the dosage form.
Older people often find it difficult to maintain balance with their eyes closed, which emphasizes the importance of vision. The greater influence of vision on orientation and balance has been observed by manipulating static and dynamic visual cues-for instance, tilting the frame of reference or moving visual scenes. Older people-particularly those prone to falls-have been reported to make significantly greater errors in subjective visual verticality and exhibit greater sway and continued center of gravity oscillation during and following visual disturbances. They also adopted hip strategies to restore balance in response to visual perturbation, indicating that they were unstable in the event of visual disturbance. These results indicate that older people may have higher levels of visual dependence than younger adults.

The underlying mechanism of visual dependence remains unclear. Visual dependence is considered a form of sensory reweighting deficit. In a situation of sensory conflict, the central nervous system must first recognize the discrepancy and reduce the weighting (suppress) of the inaccurate input while increasing the weighting of the input from the sensory systems that are deemed to provide more reliable information. This complex process of sensory organization is termed multiple-sensory reweighting and is vital in maintaining balance and orientation in a continuously changing and complex environment.

Studies have suggested that visual dependence could benefit from promoting desensitization and increased visual motion tolerance through visual adaptation and habituation exercises in vestibular rehabilitation. This may be because the majority of visually dependent adults have the comorbid symptom of visual vertigo. However, according to the National Audit Survey in the United States, one-third of patients with vestibular disorders and visual dependence lack signs and symptoms of dizziness or vertigo. Recent evidence has demonstrated that healthy older adults with greater levels of visual dependence did not have dizziness; therefore, it is unclear whether visual adaptation exercises can effectively reduce the degree of visual dependence in such people. However, visual dependence can be considered as a sensory reweighting deficit; therefore, multisensory balance training with manipulation of the visual, vestibular, and proprioceptive inputs could be an alternative for decreasing visual dependence through improving the integration and reweighting of sensory systems. In fact, multiple studies have documented that multisensory balance training improves mobility and balance in older adults with instability or a history of falls; however, few have investigated its effectiveness on visual dependence and in healthy elderly people. Therefore, the aim of the study was to investigate the effectiveness of multisensory balance training on the levels of visual dependence and sensory organization capacity in older adults.
<P>PROBLEM TO BE SOLVED: To provide an even commercially practicable method for production by which drinking water having maintaining effects on homeostasis can be mass-produced from deep marine water.  <P>SOLUTION: The method for producing the drinking water having the maintaining effects on the homeostasis comprises a first step of carrying out a membrane treatment of the deep marine water with a reverse osmosis membrane composed of a cellulose acetate membrane and affording permeate water and a second step of adding the deep marine water to the permeate water. In the first step, the pressure difference before and after the reverse osmosis membrane is set at 4.0-7.9 MPa. The pH of the permeate water is regulated to 4.8-6.8. The electroconductivity of the drinking water is set at 800-1,200 μS/cm.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Objective To explore the role and potential mechanism of caspase activation and recruitment domain-containing nucleotide-binding oligomerization domain-like receptor 3 (NLRC3) in the immune inflammatory response induced by macrophage pyroptosis in patients with rheumatoid arthritis (RA). Methods Fifty RA patients and ten healthy volunteers were selected according to inclusion criteria. Peripheral blood macrophages were extracted and divided into six groups: normal control(NC), RA macrophage model (RA-MC), RA-MC with NLRC3 overexpression, RA-MC with NLRC3 knockdown, RA-MC with STING overexpression, and RA-MC with STING knockdown groups. Macrophage pyroptosis was observed using transmission electron microscopy. The mRNA expressions of NLRC3, STING, caspase-1, and GSDMD were detected using RT-qPCR. interleukin 1β (IL-1β) and IL-18 levels in cell supernatants were measured using ELISA. Results Compared to the NC group, the RA-MC group showed characteristics of pyroptosis. Compared to the RA-MC group, the groups of RA-MC with NLRC3 overexpression and RA-MC with STING knockdown showed improved pyroptosis, while the groups of RA-MC with NLRC3 knockdown and RA-MC with STING overexpression demonstrated exacerbated pyroptosis. Compared to the NC group, the RA-MC group showed increased mRNA expression levels of STING, caspase-1 and GSDMD, as well as increased levels of the inflammatory cytokines IL-1β and IL-18, but decreased NLRC3 mRNA expression level. Compared to the RA-MC group, the groups of RA-MC with NLRC3 overexpression and RA-MC with STING knockdown showed reduced mRNA expression levels of caspase-1 and GSDMD, as well as reduced inflammatory factors, while the groups of RA-MC with NLRC3 knockdown and RA-MC with STING overexpression had opposite results. Compared to the RA-MC group, the group of RA-MC with NLRC3 overexpression showed a decreased STING mRNA expression level, while the group of RA-MC with NLRC3 knockdown demonstrated an increased level. Conclusion NLRC3 can inhibit the STING signaling pathway, reduce pyroptosis proteins caspase-1 and GSDMD, antagonize macrophage pyroptosis, and lower the levels of inflammatory cytokines IL-1β and IL-18, thereby alleviating the immune inflammatory response in RA patients.
Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
Male or female current or former smokers. FEV1/FVC \>0.7. FVC \>LLN. mMRC dyspnea score ≥1.
Lumbar sympathetic block will be performed twice on each patient: once as in the standard of practice with 10 cc 0.5% Bupivicaine and once with 75 units of Botox in 10cc of 0.5% Bupivicaine. These will be done in random order and the investigator and the patient will be blinded to which medicine they received. Two weeks after their pain has returned to 75% of their baseline they will receive the second of the blocks.

Lumbar sympathetic blockade in the standard fashion is accomplished by placing an IV in the patient. The patient is then placed face down on a fluoroscopy table. They are then prepped and draped in a sterile fashion. Conscious sedation is provided with versed and Fentanyl in the operating room with monitoring of blood pressure, pulse oximetry, and ekg. The skin is topicalized with one cc of 1% Lidocaine. The L2 lumbar vertebral body is identified and under fluoroscopic guidance a 22 gauge 6 inch spinal needle is placed at the anterolateral border of the L2 vertebral body. The retroperitoneal space is identified with a loss of resistance technique. Correct needle positioned is confirmed radiographically and appropriate spread of medications is verified by injecting 3 cc of radio opaque contrast material. The needle will be aspirated to verify that it is not intravascular. Ten cc of Bupivicaine 0.5% will then be injected in divided dose to ensure safety. Between injections the patient will be asked to report ringing in the ears or tingling in the mouth.

Subjects will be given a form asking them to rate their pain (from 0 to 10 where 0 is no pain and 10 is worst pain imaginable) at noon every day starting one week before the injection and continuing until they feel there pain has returned to baseline or two weeks whichever is longer. Days of analgesia will be the primary endpoint of the study.
AIMS: Randomized controlled trials (RCTs) testing bleeding reduction strategies using antiplatelet treatment regimens (BRATs) in acute coronary syndromes (ACS) have shown promising results, but the generalizability of these findings may be significantly influenced by the ethnicity of the patients enrolled, given that East Asian (EA) patients show different ischaemic-bleeding risk profile compared to non-EA patients.
METHODS AND RESULTS: RCTs comparing a BRAT vs. standard 12-month dual antiplatelet therapy (DAPT) in patients with ACS undergoing percutaneous coronary intervention (PCI) were selected. The primary efficacy endpoint was major adverse cardiovascular events (MACE) as defined in each trial and the primary safety endpoint was minor or major bleeding. Twenty-six RCTs testing seven different BRATs were included. The only strategy associated with a trade-off in MACE was 'upfront unguided de-escalation' in the subgroup of non-EAs (risk ratio 1.16, 95% confidence interval 1.09-1.24). All but aspirin monotherapy-based strategies (i.e. 'short and very short DAPT followed by aspirin') were associated with reduced bleeding compared with standard DAPT in both EA and non-EA patients. There were no significant differences between subgroups, but the lack of RCTs in some of the included strategies and the difference in the certainty of evidence between EA and non-EA patients revealed that the evidence in support of different BRATs in ACS undergoing PCI is influenced by ethnicity. Moreover, absolute risk reduction estimation revealed that some BRATs might be more effective than others in reducing bleeding according to ethnicity.
CONCLUSION: The majority of BRATs are associated with reduced bleeding without any trade-off in hard ischaemic endpoints regardless of ethnicity. However, the supporting evidence and relative safety profiles of different BRATs might be significantly affected by ethnicity, which should be taken into account in clinical practice.
STUDY REGISTRATION: This study is registered in PROSPERO (CRD42023416710).
In the study, 52 students will be randomly assigned to intervention (yoga) and control groups. The researcher will provide information about the purpose of the study and the study process by interviewing all the students in the sample online. All students participating in the study, who are in the yoga or control group of the study, will be given a data collection form as a pre-test by the researcher.

Hatha yoga will be applied to the students (n = 26) in the yoga group in the study. Considering the studies conducted with these students, it is planned to practice Hatha yoga for 60 minutes twice a week for three menstrual cycles (12 weeks). Yoga practice will be done online by the researcher Aslıhan Aksu (A.A.), who has a Yoga Alliance-approved yoga instructor certificate, on the determined days and times using appropriate platforms. In the control group (n=26), no intervention will be made for 12 weeks. The results will be collected through data collection forms before the yoga practice and after the 12-week yoga practice is completed. The data collection forms applied to all students in the yoga and control groups at the beginning of the study will be applied to the control group again at the end of 12 weeks. The primary expected result of the study is the effect of yoga on students' menstrual pain intensity. The secondary expected results of the study are to determine the effect of yoga on students' menstrual symptoms and quality of life.
Dexrazoxane for injection, a cardioprotective agent for use in conjunction with doxorubicin, is a sterile, pyrogen-free lyophilizate intended for intravenous administration.

Chemically, dexrazoxane is (S)-4,4’-(1-methyl-1,2-ethanediyl)bis-2,6- piperazinedione. The structural formula is as follows:

  


Dexrazoxane, an intracellular chelating agent, is a derivative of EDTA. Dexrazoxane for injection is a white to off-white or pale pink lyophilized powder or cake that melts at 191° to 197°C. It is sparingly soluble in water and 0.1 N HCl, slightly soluble in ethanol and methanol, and practically insoluble in nonpolar organic solvents. The pKa is 2.1. Dexrazoxane has an octanol/water partition coefficient of 0.025 and degrades rapidly above a pH of 7.0.

Each 250 mg vial contains dexrazoxane hydrochloride equivalent to 250 mg dexrazoxane. Hydrochloric Acid, NF is added for pH adjustment. When reconstituted as directed with the 25 mL vial of 0.167 Molar (M/6) Sodium Lactate Injection, USP diluent provided, each mL contains: 10 mg dexrazoxane. The pH of the resultant solution is 3.5 to 5.5.

Each 500 mg vial contains dexrazoxane hydrochloride equivalent to 500 mg dexrazoxane. Hydrochloric Acid, NF is added for pH adjustment. When reconstituted as directed with the 50 mL vial of 0.167 Molar (M/6) Sodium Lactate Injection, USP diluent provided, each mL contains: 10 mg dexrazoxane. The pH of the resultant solution is 3.5 to 5.5.
PURPOSE:To obtain the subject compound having remarkable sucrase-inhibiting activity and useful as an antiobestic agent and an antidiabetic agent by culturing a specific microbial strain belonging to the genus Micromonospora or Amycolatopsis. CONSTITUTION:A microbial strain belonging to the genus Micromonospora or Amycolatopsis and capable of producing the compound of formula [e.g. Micromonospora sp. SANK62390 (FERM BP-3521)] is cultured and the objective compound is separated from the culture product. The culture is preferably carried out at 28 deg.C for several days under shaking in the case of a small-scale culture. In a large-scale culture, it is preferably carried out at 28 deg.C under aeration and agitation using a tank provided with a stirrer and an aeration apparatus.
Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
This pilot randomized controlled trial aims to assess effects of a coach-guided individual online acceptance and commitment therapy (ACT) intervention on distressed stroke survivors compared to the care-as-usual control group. A total of 24 stroke survivors who meet the inclusion criteria will be recruited and randomized to either the intervention group or the control group. The intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 6 weeks through Zoom videoconferencing. Also, a one-time 1-hour booster session will be provided at 1-month follow-up to facilitate the maintenance of treatment effects. All ACT sessions will be delivered by our ACT coach, a licensed professional counselor (LPC) with substantial clinical experiences and expertise in ACT. Participants assigned to the control group will receive care as usual during the study period. Outcomes regarding mental health and ACT processes will be collected at three time points (i.e., pretest, posttest, and 2-month follow-up) and compared between groups over time. Mental health outcomes and ACT processes will be measured using self-reported questionnaires. A 30-minute individual interview also will be conducted for participants in the intervention group through Zoom videoconferencing to explore participants' experiences in the ACT intervention. The participant demographic information form will be asked to complete at pretest only, asking participants' information such as age, gender, ethnicity/race, level of education, marital status, employment status, and time since stroke.
INTRODUCTION: Hysterectomy is one of the most common surgeries performed in women. Minimally invasive methods are on the rise globally as they have been shown to decrease surgical morbidity compared with abdominal hysterectomy. Hysterectomy by vaginal natural orifice transluminal endoscopic surgery (vNOTES) is the latest innovation. It combines the vaginal approach and endoscopy via the vagina. Large pragmatic randomised controlled trials (RCTs) are lacking comparing outcomes after vNOTES, vaginal hysterectomy (VH) and laparoscopic hysterectomy (LH).
METHODS: Multicentre pragmatic RCT aiming to recruit 1000 women aged 18-75 years undergoing hysterectomy for benign disease. The RCT includes two identical substudies (groups A and B). If VH is considered safe and feasible, the patient will be randomised within group A (VH vs vNOTES). If VH is not considered safe or feasible, patients will be randomised within group B (LH vs vNOTES).
ANALYSIS: Primary outcome is the proportion of women leaving the hospital within 12 hours after surgery. Secondary outcomes are hospitalisation time, conversion rates, duration of the surgical procedure, intraoperative complications, postoperative complications and readmission.
ETHICS AND DISSEMINATION: The Ethical Board Committee at Imelda Hospital, Bonheiden, Belgium, has approved the research protocol 230704 (principal investigator). Before including patients, all centres will require local or national ethical approval. The results of the study will be published in international peer-reviewed journals.
TRIAL REGISTRATION NUMBER: NCT05971875.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical preparation used for prophylaxis and treatment of influenza. Preparation ensures to prevent infection propagation. Preparation "Antiagrippin" containing ascorbic acid, rutin, dimedrol and calcium gluconate comprises additionally paracetamol and accessory substances taken in the definite ratio of components. Preparation comprises calcium stearate and starch as accessory substances. EFFECT: prolonged time of storage of preparation. 2 cl, 1 tbl
The test device is configured of a device main body and a mobile terminal. The mobile terminal functions as an operation terminal of the device main body, and a browsing terminal for measurement data. The mobile terminal is connected to the device main body through wireless communication. The device main body wirelessly transmits the measurement data to the mobile terminal. The mobile terminal notifies the device main body of the reception data size of the measurement data. In the device main body, a determining unit collates the reception data size with the transmission data size of the measurement data and determines whether or not the measurement data is normally transmitted. A notifying unit notifies the mobile terminal of a transmission result showing that non-transmitted data is present.